Product logins

Find logins to all Clarivate products below.


Stacey Chang-Douglass

Head of Health Economics and Director in Consulting

Stacey is Head of Health Economics and Director in Consulting at Clarivate.

Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.

Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.

Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.

Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.

Latest news

News February 3, 2026
Clarivate Webinar “Intelligence Amplified in the Age of AI” Highlights How Trusted, Proprietary Data Powers Next Generation Innovation

London, UK – February 3, 2026, Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of a video webinar, Intelligence Amplified in the Age…

News February 2, 2026
Clarivate Announces Full Redemption of Remaining $100 Million Senior Secured Notes Due 2026 and Provides Update on Capital Allocation Activities

London, UK – February 2, 2026, Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that its subsidiary, Camelot Finance S.A., has redeemed the remaining $100…

News January 28, 2026
Clarivate to Report Fourth Quarter and Full Year 2025 Results on February 24, 2026

London, U.K., January 28, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the fourth…

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025